Investors Purchase Large Volume of Call Options on CryoPort (CYRX)

CryoPort Inc (NASDAQ:CYRX) was the target of some unusual options trading on Monday. Traders purchased 2,036 call options on the stock. This is an increase of 1,173% compared to the typical volume of 160 call options.

CYRX has been the subject of several analyst reports. BidaskClub raised CryoPort from a “hold” rating to a “buy” rating in a research note on Thursday, February 7th. ValuEngine raised CryoPort from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 31st. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $19.75.

Shares of CYRX stock opened at $17.45 on Wednesday. CryoPort has a 52-week low of $8.28 and a 52-week high of $18.11. The company has a debt-to-equity ratio of 0.42, a current ratio of 11.57 and a quick ratio of 11.52. The company has a market cap of $539.90 million, a P/E ratio of -56.29 and a beta of 1.10.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Thursday, May 2nd. The consumer goods maker reported ($0.08) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.08). CryoPort had a negative return on equity of 28.30% and a negative net margin of 41.61%. The firm had revenue of $6.65 million during the quarter, compared to analyst estimates of $6.56 million. During the same period last year, the company earned ($0.10) EPS. CryoPort’s quarterly revenue was up 65.4% compared to the same quarter last year. Research analysts expect that CryoPort will post -0.3 EPS for the current year.

In other news, Director Richard J. Berman sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $11.84, for a total value of $355,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.00% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the stock. Jefferies Group LLC bought a new stake in shares of CryoPort during the 1st quarter worth approximately $325,000. Geode Capital Management LLC lifted its stake in shares of CryoPort by 21.8% during the 1st quarter. Geode Capital Management LLC now owns 368,500 shares of the consumer goods maker’s stock worth $4,761,000 after acquiring an additional 65,956 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of CryoPort by 8.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 63,164 shares of the consumer goods maker’s stock worth $817,000 after acquiring an additional 4,934 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of CryoPort during the 1st quarter worth approximately $135,000. Finally, Northern Trust Corp lifted its stake in shares of CryoPort by 7.4% during the 1st quarter. Northern Trust Corp now owns 363,104 shares of the consumer goods maker’s stock worth $4,692,000 after acquiring an additional 24,993 shares during the last quarter. 49.10% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2019/05/22/investors-purchase-large-volume-of-call-options-on-cryoport-cyrx.html.

About CryoPort

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.

Further Reading: What is Depreciation?

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.